Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Operating Leases (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Operating Leases data on record, last reported at $65026.0 in Q3 2025.

  • For Q3 2025, Operating Leases fell 32.42% year-over-year to $65026.0; the TTM value through Sep 2025 reached $65026.0, down 32.42%, while the annual FY2024 figure was $53598.0, 76.68% down from the prior year.
  • Operating Leases reached $65026.0 in Q3 2025 per GANX's latest filing, down from $92851.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $695053.0 in Q4 2021 and bottomed at $30589.0 in Q1 2025.
  • Average Operating Leases over 5 years is $313006.5, with a median of $263460.0 recorded in 2023.
  • Peak YoY movement for Operating Leases: soared 73.62% in 2021, then tumbled 91.99% in 2025.
  • A 5-year view of Operating Leases shows it stood at $695053.0 in 2021, then tumbled by 36.44% to $441784.0 in 2022, then plummeted by 47.97% to $229855.0 in 2023, then crashed by 76.68% to $53598.0 in 2024, then grew by 21.32% to $65026.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $65026.0 in Q3 2025, $92851.0 in Q2 2025, and $30589.0 in Q1 2025.